BACKGROUND: Since rheumatoid arthritis is the most common in the world inflammatory arthropathy, being highly disabling and causing great impact of high cost, we seek to offer the patient treatment options and quality of life through the establishment of a timely and effective treatment, recognizing those prior to establish predictors of response given therapy. There are few studies to establish those factors appropriate response to the start of biological therapy with abatacept, so this study is to determine what those factors are possible. METHODS: This was a cross-sectional analytical study of 94 patients diagnosed with RA, assessed to determine possible variables that influence the biological response to abatacept therapy type. 67 were included in the regression model, which are those patients in whom it was possible to measure the response to treatment (EULAR response) through the determination of the DAS 28 and thus discriminate two comparison groups (response and nonresponse ). DISCUSSION OF RESULTS The presence of high activity of the disease at the start of biological therapy increases the likelihood of response to treatment compared to the group with low /moderate disease activity; OR 4.19 - 95% CI (1.18 - 14.9), (p 0.027). The absence of bone erosions increases the probability of adequate response to biological therapy compared with those erosions, with an OR 3.1 (1.01 to 9.55), (p 0.048). ESR and the presence of extra-articular manifestations: other data of interest in the bivariate analysis found. Regarding the variables or characteristics as predictors of response to treatment with abatacept, they are studies that corroborate the findings of this study, regarding the high DAS 28 score at the start of therapy (9, 12). CONCLUSIONS: There are several variables that determine the biological response to different handling of AR. It is essential to assess these factors individually in order to achieve effectively control the disease and improve the quality of life of the individual (personalized medicine). There are variables such as high disease activity and the absence of erosions as predictors of response in abatacept therapy.